5-Amino-1MQ vs AOD-9604
Side-by-side comparison of key properties, dosing, and research.
Fat Loss & Metabolic
5-Amino-1MQFat Loss & Metabolic
AOD-9604- Summary
- 5-Amino-1MQ is a small-molecule NNMT (Nicotinamide N-methyltransferase) inhibitor that raises intracellular NAD+ levels and promotes fat burning. It is notable for targeting adipose tissue directly, reducing fat cell size and number while increasing metabolic rate.
- AOD-9604 is a modified fragment of human growth hormone (residues 177-191) with an additional tyrosine residue that significantly enhances bioavailability. Originally developed as an anti-obesity drug by Metabolic Pharmaceuticals, it stimulates lipolysis and inhibits lipogenesis without the diabetogenic effects of full GH.
- Half-Life
- Estimated 4–8 hours
- 30-45 minutes injectable; longer with nasal spray formulation
- Admin Route
- Oral
- SubQ, Intranasal, Oral
- Research
- —
- —
- Typical Dose
- 50–100 mg
- 300-600 mcg
- Frequency
- Once to twice daily
- Once daily
- Key Benefits
- Raises intracellular NAD+ levels
- Directly targets adipose tissue for fat reduction
- Reduces fat cell size and differentiation
- Increases basal metabolic rate
- SIRT1 activation for metabolic regulation
- No stimulant cardiovascular side effects
- Synergistic with intermittent fasting and caloric restriction
- May have anti-aging metabolic benefits
- Selective fat loss without anabolic side effects
- No effect on blood glucose or insulin resistance
- Improved bioavailability over Fragment 176-191
- GRAS (Generally Recognized As Safe) status in Australia
- Potential cartilage repair and anti-inflammatory properties
- Does not suppress natural GH production
- Side Effects
- Generally well-tolerated in available studies
- Mild GI discomfort (rare)
- Limited long-term human data
- Localized injection site reactions
- Headache (rare)
- Hypoglycemia risk in combination with insulin (very rare)
- Stacks With
- —
- —